Drug intelligence / Profile preview

TK61406

Development stage: Unknown
Lead developer: Tokai Pickling
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

TK61406 is a proprietary probiotic strain of *Lactobacillus plantarum* developed by the Japanese food company Tokai Pickling Co., Ltd. (Tokai Tsukemono). Originally isolated from traditional Japanese fermented vegetables, the strain is characterized by its potent ability to induce the production of interleukin-12 (IL-12) from immune cells such as macrophages and dendritic cells. This induction of IL-12 is thought to promote a Th1-type immune response, potentially offering benefits for immune regulation and resistance to infections. TK61406 has been evaluated in clinical trials for safety and its effects on immune markers and organ-related parameters in healthy adults, positioning it as a functional food ingredient or nutraceutical for immune support.

Other names: Lactobacillus plantarum TK61406

Targets

IL12 (Interleukin-12)

Beyond the preview

Go deeper on TK61406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TK61406.

Explore the full profile